NCT00725920View on ClinicalTrials.gov

Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

Topiramate

patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day

DRUG

placebo control group

initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day

Trial Locations (1)

04023-061

Federal University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

Federal University of São Paulo

OTHER

NCT00725920 - Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients. | Biotech Hunter | Biotech Hunter